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Direct biochemical functional analysis of im-
planted cells in human brain during life is not
possible. However, one can obtain specific
regional cerebral biochemical information using
special radiotracer techniques and positron
emission tomography (PET). The information
carriers are tracer substances, labelled with
short-lived positron emitting radionuclides (e.g.
C or SF), which, after administration to
healthy volunteers or patients, are distributed in
space and time according to their pharmaco-
kinetic properties. Comparison of the time
course of count rates in brain regions with
specific tracer uptake to those in brain reference
regions allows quantification of specific tracer
uptake in terms of metabolic trapping or binding
to receptor sites. Quantification may be at-
tempted through application of rigorous math-
ematical kinetic models or via simple but robust
measures like ratios of count rates between two
brain regions.
Several PET radiotracers now exist to investi-
gate various aspects of the dopaminergic nigro-
striatal neurotransmitter system. Pathophysio-
logical changes at the level of the striatum can
be detected and followed longitudinally, or
pharmacodynamic interactions with drugs can be
studied.
6-[8F]-Fluoro-L-dopa is an L-dopa analogue
which is specifically trapped in the dopaminergic
nigrostriatal nerve terminals after decarboxyla-
tion to the amine form. 6-[lSF]-Fluoro-L-dopa
uptake is thus a measure of striatal dopaminer-
gic nerve terminal decarboxylation capacity,
which at the same time parallels nerve terminal
dopamine storage capacity. This tracer does not
measure endogenous dopamine concentration,
since kinetically it is not exchanging with that
pool. However, 6-[18F]-fluoro-L-dopa uptake
does mimic exogenous L-dopa uptake into the
brain both qualitatively and quantitatively. In
Parkinson’s disease 6-[8F]-fluoro-L-dopa up-
take is decreased in striatum, particularly in
putamen (40-50% of control values) and to a
lesser degree in caudate nucleus (80% of
controls).
[nC]-Raclopride, a dopamine-D2 antagonist,
binds selectively to dopamine-D2 receptors
which are, for the most part, post-synaptically
located on striatal projection neurons. In early
stage Parkinson’s disease we have found in-
creased specific dopamine-D2 receptor binding
in putamen (20%) in proportion to the severity
of clinical signs and symptoms. Probably this
correlates directly with the presynaptic
dopaminergic deficit as assessed by 6-[8F]
fluoro-L-dopa.
The pattern of uptake of 6-[8F]-fluoro-L
dopa and [XlC]-raclopride in putamen and
caudate nucleus in Parkinson’s disease contrasts
with that seen in other neurodegenerative dis-
orders.
The effect of striatal transplantation of tissue
in patients with dopaminergic neurotransmitter
damage can be investigated by comparing pre-
and post-operative PET tracer uptake using the
above-mentioned dopaminergic radiotracers.
PET scans after autologous adrenal medulla
implantation into striatum neither showed
changes in dopamine-D2 receptor binding in two
patients using the tracer [lC]-raclopride (Ann
Neurol 1987; 22: 457-468), nor changes in 6-
[18F]-fluoro-L-dopa or [nC]-nomifensine uptake
in two other patients (personal results, un-
published). One study on 5 patients also did not
find significant changes of 6-[18F]-fluoro-L-dopa
uptake after implantation (Can J Neurol Sci
16:305-309). All the patients mentioned above
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did not show or only transiently showed clinical
improvements.
PET scans on patients who received fetal
dopaminergic neurons have been systematically
performed in only a few cases. The results on 4
patients have been extensively published (Arch
Neurol 1989; 46: 615-631; Science 1990; 247:
174-177; Ann Neurol 31:155-165 and 166-173).
Mainly 6-[8F]-fluoro-L-dopa was used as a
tracer in these studies. Patients 1 and 2
(implants in putamen and caudate nucleus in
one hemisphere) only mildly improved clinically
and showed only little concomitant improvement
of 6-[8F]-fluoro-L-dopa uptake on the sites of
implantation. Patients 3 and 4 (implanted only in
putamen on one side) were operated using im-
proved techniques of tissue preparation and
implantation. They showed marked clinical
improvement over the course of several months
paralleled by a significantly increased 6-[8F]
fluoro-L-dopa uptake on the site of the im-
planted putamen. This tracer increase was main-
tained over a period of 3 years after operation.
At the same time the tracer uptake in the non-
operated sites showed a progressive decrease in
these two patients.
Two severely affected MPTP-induced parkin-
sonian patients have also been investigated using
PET before and after bilateral fetal grafting into
putamen and caudate nucleus (Rest Neurol
Neurosc 1992; 4(3)" 181). PET 6-[XSF]-fluoro-L
dopa scans showed a marked increase of uptake
at 1 year after operation concomitant with
significant improvement in motor function.
Although the total number of patients studied
to date has of necessity been small, these sub-
jects were carefully selected, thoroughly investi-
gated and followed-up. The degree of survival
and outgrowth of fetal cells after striatal implan-
tation is associated with a corresponding im-
provement of 6-[SF]-fluoro-L-dopa uptake on
the implanted sites. PET applied in this way thus
provides an effective means to check the success
of implantation procedures.